Alzheimer’s disease is initiated by the accumulation of amyloid-beta aggregates around neurons in the aging brain. A key factor that drives aggregation of amyloid-beta is high concentrations of the peptide. Normally, amyloid-beta is at low levels because it is readily cleared from the brain by several mechanisms including its drainage system (the glymphatic system). This system needs a special water channel (Aqp4) to control fluid flow. We recently found a new form of Aqp4 can be generated in the brain by a process called stop codon readthrough. With Hope Center support, we aim to test whether this new form of Aqp4 can be used to drive better clearance of amyloid-beta in Alzheimer’s test models in order to keep levels low and reduce toxic accumulation. We also aim to identify genes and drugs that can make more of this Aqp4 form in the brain.